Podcasts about Luminex

In this installment of the Longevity & Aging Series, Dr. Ming Yu and Namita Hattangady from the Fred Hutchinson Cancer Center in Seattle, join host Dr. Evgeniy Galimov to discuss a research paper they co-authored that was published as the cover for Volume 16, Issue 4 of Aging (Aging-US), entitled, “Mapping the core senescence phenotype of primary human colon fibroblasts.” DOI - https://doi.org/10.18632/aging.205577 Corresponding authors - William M. Grady - wgrady@fredhutch.org, and Ming Yu - myu@fredhutch.org Video interview - https://www.youtube.com/watch?v=eqSa7My_a7w Interview transcription - https://www.aging-us.com/interviews/longevity-aging-series-s2-e2-dr-ming-yu-and-namita-hattangady Abstract Advanced age is the largest risk factor for many diseases and several types of cancer, including colorectal cancer (CRC). Senescent cells are known to accumulate with age in various tissues, where they can modulate the surrounding tissue microenvironment through their senescence associated secretory phenotype (SASP). Recently, we showed that there is an increased number of senescent cells in the colons of CRC patients and demonstrated that senescent fibroblasts and their SASP create microniches in the colon that are conducive to CRC onset and progression. However, the composition of the SASP is heterogenous and cell-specific, and the precise senescence profile of colon fibroblasts has not been well-defined. To generate a SASP atlas of human colon fibroblasts, we induced senescence in primary human colon fibroblasts using various in vitro methods and assessed the resulting transcriptome. Using RNASequencing and further validation by quantitative RT-PCR and Luminex assays, we define and validate a ‘core senescent profile' that might play a significant role in shaping the colon microenvironment. We also performed KEGG analysis and GO analyses to identify key pathways and biological processes that are differentially regulated in colon fibroblast senescence. These studies provide insights into potential driver proteins involved in senescence-associated diseases, like CRC, which may lead to therapies to improve overall health in the elderly and to prevent CRC. Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.205577 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, senescence, senescence associated secretory phenotype, SASP, colorectal cancer, cancer About Aging-US The mission of the journal is to understand the mechanisms surrounding aging and age-related diseases, including cancer as the main cause of death in the modern aged population. The journal aims to promote 1) treatment of age-related diseases by slowing down aging, 2) validation of anti-aging drugs by treating age-related diseases, and 3) prevention of cancer by inhibiting aging. (Cancer and COVID-19 are age-related diseases.) Please visit our website at https://www.Aging-US.com​​ and connect with us: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

[Full Episode] Join us in this enlightening episode of Driving Impact as host Katheline sits down with Carmen Zella, the visionary founder and chief creator behind Now Art. Carmen takes us on an inspiring journey through her impactful work in public art, from groundbreaking street art movements to immersive urban installations like Luminex. Discover how Carmen's dedication to integrating art into urban environments fosters community, sparks innovation, and transforms cities. Hear about her personal odyssey, the challenges she's faced as a woman in the art world, and her unwavering commitment to making art accessible to all. Whether you're an art enthusiast, a budding entrepreneur, or someone passionate about driving positive change, this episode offers valuable insights and inspiration. Tune in and explore how art can heal, unite, and elevate our societal consciousness.   Chapters: 00:00 - The Importance of Art in Communities 01:00 - Welcome to Driving Impact with Carmen Zella 02:00 - Carmen Zella's Journey to Finding Her Purpose 04:00 - The Transformative Power of Immersive Theater 06:00 - From London to Montreal: Embracing Interdisciplinary Arts 08:00 - The Role of Artists in Urban Environments 10:00 - Luminex: A Fusion of Art and Technology 12:00 - The Impact of Public Art on Communities 14:00 - The Impact of Art on Society 15:00 - Exploring the Intersection of Art and AI 16:00 - The Role of Technology in Public Art 17:00 - The Vision and Mission of the Foundation 18:00 - Reviving the Triforium Project 19:00 - Challenges and Opportunities in Public Art 20:00 - The Unifying Power of Art 21:00 - Advice for Aspiring Change-Makers  

Anthony has done a lot of installs in houses of worship. With their limited budgets, you want to get all your wiring right while the conduit is open and the drywall has yet to be done. And sometimes that means pressing your customer a little harder to get a more detailed and explicit Control Intent Narrative which will help you get it right the first time. Listen in and find out the intricacies of a niche lighting control project type! And sometimes that means pressing your customer a little harder and out of their comfort zone in order to get it right the first time. Anthony is a seasoned lighting designer with over a decade of experience in the industry. His career has seen him collaborate with leading technical brands, such as Luminex, to train, design, and consult on numerous projects within the house of worship, theater, and entertainment markets. As a Lighting Designer in Orlando, FL, Anthony has played a pivotal role in designing, programming, and managing sophisticated lighting systems and designs. Here, Anthony also honed his networking skills in an AVL (Audio, Visual, Lighting) environment, where he excelled in designing, programming, and training individuals to operate, configure, and confidently use their systems. In addition to his hands-on industry experience, Anthony has dedicated time to education by staying active in his local industry market as well as teaching in his local colleges. In this role, he imparts his extensive knowledge of entertainment and stage production to the next generation of industry professionals. Outside of work Anthony enjoys travel to the nation's national parks, hiking, and cycling his way through the beautiful outdoors! Anthony's blend of practical experience and passion for teaching positions him as a valuable asset in any lighting design project, whether it be in a house of worship, a theater, or a grand entertainment venue.

In het podcastdeel praten we verder over wat voortkwam uit die halving: het Runes-protocol van ontwikkelaar Casey Rodarmor. Zijn nieuwste idee lanceerde met de halving van Bitcoin, die Diezelfde Rodarmor was twee jaar geleden verantwoordelijk voor het idee van de ordinals en inscriptions. Een idee dat NFT's en zelfs memecoins mogelijk maakte op Bitcoin. Het werd een behoorlijke hype, die zo nu en dan zelfs een flinke file op het netwerk veroorzaakte. Welke innovatie brengen Runes? We praten bij met Bart Mol, host van Satoshi Radio en fanatiek volger van alle experimenten op en rond Bitcoin. En dit mag je zeker een experiment noemen, want je kan deze nieuwe Runes rustig zien als een evolutie op de BRC-20 tokens die het Bitcoinnetwerk toch een aantal weken in hun greep hadden. Dat lijkt nu weer het geval. De eerste serie Runes van Casey Rodarmor, genaamd Uncommon Goods, zorgde direct voor een kleine hype. Iedere Bitcointransactie kan een 'Uncommon Good' minten, maar de kosten voor een simpele transactie zijn inmiddels flink opgelopen. Het lijkt een voorbode voor wat er de komende maanden komen gaat. Wat moet je, als volger van de cryptowereld allemaal weten van die runes? Op welke websites kan je handelen in dit soort tokens? En hoe weet je of jouw wallet het Runes-protocol wel ondersteund? En ook als je van plan bent niet mee te doen (en daar zijn genoeg redenen voor) dan is het handig om te weten wat dit nieuwe idee voor gevolgen heeft. Het kan namelijk zomaar dat transacties fors duurder worden of dat meer mensen gebruik gaan maken van de zogeheten 'accelerators', maniertjes van miners om, buiten het transactiesysteem van Bitcoin om, geld aan te nemen en bepaalde transacties vooraan te zetten. Co-host is Daniël Mol. Gasten Bart Mol Daniël Mol Links Een must-have voor iedere Bitcoiner, Mempool.Space Handelen in runes? Magic Eden Zelf aan de slag met runes? Luminex.io Host Herbert Blankesteijn Redactie Daniël MolSee omnystudio.com/listener for privacy information.

I'D RATHER HAVE IT AND NOT NEED IT, THEN NEED IT A NOT HAVE IT-Thinking Out Loud w/Friends # 201 - Topics Discussed (03/27/2024):Speaker System Timing, Clock Throughput, Digital Audio Consoles, Clocking, Special Guest Appearance By Charo, Gps Clock, Realtime With Bill Maher, Luminex Switches, Marijuana, LGBTQ, Realtor, 750-Pound Alligator, Visa, Mastercard, Commission, Bridge Collapse, Donuts, Real Estate Commission, Costco Is Selling Gold Bars And Silver Coins. Join your host Jan Landy and his amazingly knowledgeable panel of friends for an entertaining robust discussion offering opinions on current events and life in general on Zoom every Wednesday at 5 PM  - Pacific (UTC-7)/ 8 PM EDT Topics Discussed (03/31/2024)The team engaged in a broad range of discussions covering topics from pet ownership to technical issues related to clock systems and GPS, with an emphasis on the importance of precise timekeeping in digital systems. They also explored the use of analog consoles, the limits of human hearing, and the significance of having a master clock in their equipment. Additionally, they delved into personal experiences, the performance and quality of Luminex switches, issues related to audio quality in live settings, and the technical aspects of using digital audio equipment. The conversation ended with discussions on personal updates, upcoming events, and popular restaurants, as well as concerns about the decline in intelligence and critical thinking skills in Americans.

BUFFALO, NY- February 29, 2024 – A new #research paper was #published on the #cover of Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 16, Issue 4, entitled, “Mapping the core senescence phenotype of primary human colon fibroblasts.” Advanced age is the largest risk factor for many diseases and several types of cancer, including colorectal cancer (CRC). Senescent cells are known to accumulate with age in various tissues, where they can modulate the surrounding tissue microenvironment through their senescence associated secretory phenotype (SASP). Recently, researchers showed that there is an increased number of senescent cells in the colons of CRC patients and demonstrated that senescent fibroblasts and their SASP create microniches in the colon that are conducive to CRC onset and progression. However, the composition of the SASP is heterogenous and cell-specific, and the precise senescence profile of colon fibroblasts has not been well-defined. In this new study, to generate a SASP atlas of human colon fibroblasts, researchers Namita Ganesh Hattangady, Kelly Carter, Brett Maroni-Rana, Ting Wang, Jessica Lee Ayers, Ming Yu, and William M. Grady from Fred Hutchinson Cancer Center and the University of Washington School of Medicine induced senescence in primary human colon fibroblasts using various in vitro methods and assessed the resulting transcriptome. “[...] we utilized various relevant stressors to induce senescence in primary cultures of colon fibroblasts and perform RNA sequencing (RNASeq) to define an atlas of stressor-specific senescent profiles and a core senescent profile that is commonly regulated by all senescence inducers.” Using RNA Sequencing and further validation by quantitative RT-PCR and Luminex assays, the team define and validate a ‘core senescent profile' that might play a significant role in shaping the colon microenvironment. They also performed KEGG analysis and GO analyses to identify key pathways and biological processes that are differentially regulated in colon fibroblast senescence. These studies provide insights into potential driver proteins involved in senescence-associated diseases, like CRC, which may lead to therapies to improve overall health in the elderly and to prevent CRC. “Further studies will be needed to address the limitations of our study and to translate our understanding of the SASP and disease into clinical care.” DOI - https://doi.org/10.18632/aging.205577 Corresponding authors - William M. Grady - wgrady@fredhutch.org, and Ming Yu - myu@fredhutch.org Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.205577 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, senescence, senescence associated secretory phenotype, SASP, colorectal cancer, cancer About Aging-US Launched in 2009, Aging-US publishes papers of general interest and biological significance in all fields of aging research and age-related diseases, including cancer—and now, with a special focus on COVID-19 vulnerability as an age-dependent syndrome. Topics in Aging-US go beyond traditional gerontology, including, but not limited to, cellular and molecular biology, human age-related diseases, pathology in model organisms, signal transduction pathways (e.g., p53, sirtuins, and PI-3K/AKT/mTOR, among others), and approaches to modulating these signaling pathways. Please visit our website at https://www.Aging-US.com​​ and connect with us: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc Media Contact 18009220957 MEDIA@IMPACTJOURNALS.COM

Christian Kargl-Simard, President and CEO of Adventus Mining (TSX.V:ADZN - OTCQX;ADVZF) ("Adventus" or the "Company") joins me to discuss the announced merger with Luminex Resources. Both companies are focused in Ecuador, with Adventus holding the advanced development stage El Domo-Curipamba copper-gold project and Luminex holding 13 earlier stage exploration projects in country.    We initially introduce the merger and discuss what the combined company will focus on project wise. I have Christian outline the work needed to bring the El Domo Project into construction and how the combined company will balance building a mine while continuing to manage a large number of projects in country. We also discuss the financing announced with the merger and where the funds will be allocated. For a final comment I ask Christian about the political environment in Ecuador with the newly elected government.   Please email me with any follow up questions you have for Christian. My email address is Fleck@kereport.com.   Click here to visit the Adventus website and read over the full news release announcing the merger.

We sit down with Marshall Koval of Lumina Gold for an introduction and development update on their Cangrejos Project in Ecuador. Lumina recent secured funding off of a stream deal with Wheaton Precious Metals and will look to advance the project into construction in due time. We talk a lot about Ecuador as a mining jurisdiction and also get small glimpse into the Luminex and Adventus Mining deal recently announced.

Good is the founder of MetaBRC and the BRC-20 $MXRC. MetaBRC came onto the scene shortly after the BRC-20 craze caught some attention. After partnering with Luminex to launch $MXRC, which is considered one of the most hype mints in the BRC-20 space, the fallout from the "botted" mint caused a ton of controversy across the sector. Now Good and MetaBRC fins themselves building their way out from the lows of the project. |Good|• Twitter → https://twitter.com/atgoodm• Website → https://www.metaxrc.xyz/|CONNECT WITH JAKE|• Instagram → https://www.instagram.com/jakegallen/• Twitter → https://twitter.com/jakegallen_• Facebook → https://www.facebook.com/JakeNGallen• Linkedin →  https://www.linkedin.com/in/jake-gall...|FOLLOW AND SUBSCRIBE THE PODCAST|• Website → https://www.jakegallen.com/• Youtube → Subscribe to this page• Apple Podcasts → https://podcasts.apple.com/us/podcast...• Spotify → https://open.spotify.com/show/7hQdRAz...• Google Podcasts → https://podcasts.google.com/?feed=aHR...• RSS Feed → https://feeds.buzzsprout.com/1005154.rss• Website → https://solo.to/theguestlistpod• Media Host → https://theguestlistpod.buzzsprout.com/

Jerry is the Co-Founder of Luminex and DogePunks as well as the creator of BRC-69. Luminex is the top BRC-20 launchpad in the Ordinal space, assisting with the launch of $OXBT and $MXRC. Dogepunks is an early Ordinal PFP project and BRC-69 is an early generative NFT standard that predates the implementation of recursive inscriptions.|Jerry|• Twitter → https://twitter.com/0xJerry543• Website → https://luminex.io/|CONNECT WITH JAKE|• Instagram → https://www.instagram.com/jakegallen/• Twitter → https://twitter.com/jakegallen_• Facebook → https://www.facebook.com/JakeNGallen• Linkedin →  https://www.linkedin.com/in/jake-gall...|FOLLOW AND SUBSCRIBE THE PODCAST|• Website → https://www.jakegallen.com/• Youtube → Subscribe to this page• Apple Podcasts → https://podcasts.apple.com/us/podcast...• Spotify → https://open.spotify.com/show/7hQdRAz...• Google Podcasts → https://podcasts.google.com/?feed=aHR...• RSS Feed → https://feeds.buzzsprout.com/1005154.rss• Website → https://solo.to/theguestlistpod• Media Host → https://theguestlistpod.buzzsprout.com/

Erfahrt alles über den Marktvorsprung von Lido Finance und welche vorteile Lido Finance mit sich bringt und wie können Anleger davon profitieren können?Zudem werfen wir einen Blick auf eine Hausdurchsuchung bei dem Gründer der renommierten Kryptobörse Kraken. Ihr erfahrt außerdem, welche Meinung die US-amerikanische Großbank JPMorgan über Bitcoin ETFs vertritt.Natürlich halten wir euch auch in dieser Folge über den Krypto-Chart und die Floorpreise auf Opensea auf dem Laufenden. Zudem werfen wir einen Blick auf die neuesten Entwicklungen des NFT-Marktplatzes Blur und welche neuen Funktionen dieser liefert.Des Weiteren diskutieren wir einen Seitenhieb des Ethereum-Gründers, unzufriedene Krypto-Unternehmen und das Vorhaben von Luminex, die Bitcoin Ordinals Technologie kostengünstiger zu gestalten.https://www.7art.io/bibi-beck/pop-genesis-collection** weitere freiwillige Unterstützung:https://www.patreon.com/user?u=86396667Newsletter Barista Insights by Mic_Sebhttps://tab728b31.emailsys1a.net/247/735/e3ee874dc3/subscribe/form.html?_g=1695576545ALL IN NFT Homepage:https://www.allinnft.de/ALL IN NFT Merchandising Shop:https://all-in-nft.myshopify.com/Opensea Kollektion ALL IN NFT:https://opensea.io/assets/ETHEREUM/0x71608b3551895385637d59c3713e7369ecac2e97/0Linktree :https://linktr.ee/mic_sebDiscord: https://discord.gg/4js6Pg7FJkTwitter: @MicSeb91https://twitter.com/MicSeb91Twitch: https://twitch.tv/mic_sebYouTube: All in NFThttps://www.youtube.com/@Mic_Seb**Blockpit Code für deine einfache Steuererklärung mit Krypto und NFT Wallets:https://blockpit.cello.so/v7peWE3ssIIKontakt:Sebastian@allinnft.deGM Coffee Handy:+491733544148Bei den oben genannten Themen handelt es sich um keine Anlageberatungen. Der Podcast dient lediglich der Unterhaltung.Die mit ** gekennzeichneten Links sind sogenannte Affiliate-/ oder Unterstützungs-Links. Kommt über einen solchen Link ein Einkauf zustande, werde ich mit einer Provision beteiligt. Für Dich entstehen dabei keine Mehrkosten. Wo, wann und wie Du ein Produkt kaufst, bleibt natürlich Dir überlassen. --- Send in a voice message: https://podcasters.spotify.com/pod/show/sebastian-michels7/message

Overnighters, Episode 599: Bieber's $1.2M NFT Loss BlackRock Refiles for Bitcoin ETF HK Urged to Launch Stablecoin and More The TL;DL   Bieber's $1.2M NFT Loss - Pop icon Justin Bieber faces a significant loss after the value of his Bored Ape Yacht Club NFT plummeted, leading to speculations about the nature of his investment. BRC-69: New Ordinal Standard - The Bitcoin Ordinals world welcomes a new standard, BRC-69, introduced by Luminex. This innovation simplifies the creation of recursive ordinals and reduces inscription costs. BlackRock Refiles for Bitcoin ETF - Investment giant BlackRock refiles for a Bitcoin ETF with Nasdaq, a move that could potentially change the landscape of Bitcoin ETFs and address SEC's concerns. Winklevoss Shares “Final Offer” - Gemini co-founder Cameron Winklevoss makes a final offer in the ongoing Genesis debt-restructuring talks, potentially ending months of negotiations. HK Urged to Launch Stablecoin - Experts urge the Hong Kong government to issue its own stablecoin, HKDG, to compete with existing stablecoins like USDT and USDC, and strengthen Hong Kong's fintech capabilities. CBDC Alert(UK, China) - The UK prioritizes privacy for a potential Digital Pound while China tests its own digital currency, the Digital Currency Electronic Payment (DCEP), in the city of Jinan. Crypto Overnighter Podcast (7/4/2023): Welcome back to the Crypto Overnighter with your host, Nikodemus. We provide nightly updates on cryptocurrency, NFTs, the metaverse, and the surrounding industry. Remember, this show does not offer financial advice. Email: nick@cryptoovernighter.com Salem Friends of Felines: https://sfof.org/ Twitter: https://twitter.com/CryptoCorvus1

Paul connects with Luminex Resources for a general discussion on the exploration work being done at Cuyes West.

Less crime, closer community & better economy...this isn't a wish list but statistics revealed these are the actual side effects of public art as experienced by the South Park neighborhood in downtown Los Angeles during the Luminex event.  How is this possible?  Listen as the Executive Director of the South Park BID, Ellen Riotto, shares stories of South Park's experience of Luminex 2022 and other Public Art installations.References:South Park BIDsouthpark.laLuminexhttps://luminexla.comYoutube of Luminex 2022Luminex2022Jane Golden's Interviewhttps://clss.studio/blogs/vessel-art-as-a-doorway/jane-golden-art-as-an-antidoteFind us online:Website:http://www.clss.studioEmail:leah@leahsmithson.comchanningsmithson@gmail.comHang out with us on Instagram:@leahsmithsonart@justglazechanningEarn yield on digital assetshttps://uphold.com/signup?referral=d8b2d5cb89Support the show

To access the full interview visit https://b2binterviews.com/luminex-resources .B2B (00:01): Our guests today are Marshall Koval, Chief Executive Officer, and Scott Hicks, VP Corporate Development and Communications at Luminex Resources. Luminex trades on the TSX Venture Exchange under the ticker LR and OTCQX symbol LUMIF. Good day gentlemen. Thank you for joining us today on B2B Interviews.B2B (00:31): Gentlemen, I thought you might begin with a brief introduction and overview of the company.MK (00:35): Sure, Todd. Luminex was a spin out from its sister company Lumina Gold in 2018 and the strategy of our group, which we call the Lumina Group, has really been to separate our most advanced projects, which at the time was the one in Lumina Gold, and then spin out the other assets and look to do the same thing over time and create value for shareholders that way. All the projects we had in Ecuador at the time, with the exception of Cangrejos, went into Luminex. Our main project today is the Condor Project, which is about a six and a half million out sold project with a bunch of different deposits comprising that and then a very large land package throughout the rest of Ecuador with a heavy focus on the trend below and above Fruta del Norte and Mirador, which are the two operating mines in country right now. Our work is continuing at Condor with money that we raise in the capital markets and we're onto some pretty new exciting drill results there in an area we call Condor North. Then we have partnerships on some of our early-stage copper projects. We have a partnership with Anglo American, obviously a very large-scale copper producer. They're working on our Pegasus project in the north of the country and we have a partnership with Jogmec, which is a Japanese group, on our Arcadias project and they're doing some drilling there on a copper pour free target. Then the rest of the projects in the portfolio, we look to continue doing early-stage field work on those and we're continually evaluating other partnerships to help de-risk these projects without necessarily risking our capital, so it's a bit of a mixed strategy in this company. We have Condor, which is the gold project that we're using our own money on, and then taking a bit of a partnership approach on a lot of these earlier stage copper projects throughout the country.To access the full interview visit https://b2binterviews.com/luminex-resources .Access all of our exclusive CEO interviews and curated content as well as our terms, policies and 17B Disclosures at https://b2binterviews.com/ and follow us on social for alerts and updates as new content goes live.Twitter: https://twitter.com/b2binterviewsLinkedIn: https://www.linkedin.com/company/b2binterviews ...

Foot -and- mouth disease (FMD) is an acute, highly contagious disease of cloven-hoofed animals with impacts on farming and is responsible for major economic losses. Serological assays that measure FMDV-specific antibodies are used to monitor the presence of FMDV, for checking quality of FMD vaccine and levels of post-vaccination immunity. The aim of this work was to develop a multiplex immunoassay with recombinant empty viral capsids for FMD serological diagnosis using Luminex technology. Such a test could be used as an indicator of pre-exposure of FMDV or vaccination and to estimate immune protection in a single reaction and from a single sample against all 7 serotypes

In this episode, we chat with Scott Hicks, VP of Corporate Development & Communications for Luminex Resources, a Vancouver-based Canadian & precious metals exploration and development company focusing on a Gold and Copper project in Ecuador. Over the last decades, Scott has worked on a variety of equity, debt, and advisory assignments in Canada and Australia. He talks about the company, its projects, and the general outlook for commodities. Luminex Resources is one of Ross Beaty's development companies so be sure to listen.   KEY TAKEAWAYS Luminex has the largest gold deposit in Ecuador, one of the biggest in the world, which also contains billions of pounds of copper. In 2022, the focus is their gold drilling programs and are advancing permitting for their vanadium and other projects. Their Ecuador-based partners include Anglo American and JOGMEC. Much of Ecuador has not been thoroughly explored using modern techniques. In 2013/14, the government began to actively encourage mining once again. The infrastructure in Ecuador is excellent, with good roads, hydropower, modern port facilities, and plenty of water. Many communities welcome mining, but in certain areas, there is some resistance. There is potential for more vanadium redox battery usage, so Luminex has a small company targeting that metal. Vanadium batteries don´t degrade, which makes a leasing model viable, that reduces the upfront costs involved in their use. Luminex has a good mix of assets in mining-friendly jurisdictions. The price outlook for gold is positive. In the podcast, Scott explains why he believes that is the case. With copper, grades from existing mines are degrading and new facilities are not coming on stream fast enough to meet demand. So, the copper price should remain strong. The company is also investing in and incubating other people´s mining projects. Examples of which are shared in the podcast.   BEST MOMENTS ‘We are sitting at about 17 million ounces of gold right now and about 2.2 billion pounds of copper. ´ ‘In Ecuador, the permitting process… is actually pretty fast.' ‘It´s early days in the vanadium space... but we´ve seen prices north of $600 a tonne for pig iron.'   EPISODE RESOURCES Websites: https://luminagold.com/ https://luminexresources.com/ https://strategic-res.com/   Twitter: @Scott_ITBM @lumina_gold @LuminexRes @StrategicRes   VALUABLE RESOURCES Email: rob@mining-international.org Website: https://www.mining-international.org/ LinkedIn: https://www.linkedin.com/in/rob-tyson/ Twitter: https://twitter.com/MiningRobTyson Facebook: https://www.facebook.com/DigDeepTheMiningPodcast/ Instagram: https://www.instagram.com/theminingpodcast/ YouTube: https://www.youtube.com/c/DigDeepTheMiningPodcast/videos   ABOUT THE HOST Rob Tyson is an established recruiter in the mining and quarrying sector and decided to produce the “Dig Deep” The Mining Podcast to provide valuable and informative content around the mining industry. He has a passion and desire to promote the industry and the podcast aims to offer the mining community insight into people's experiences and careers covering any mining discipline, giving the listeners helpful advice and guidance on industry topics. Rob is the Founder and Director of Mining International Ltd, a leading global recruitment and headhunting consultancy based in the UK specializing in all areas of mining across the globe from the first world to third world countries from Africa, Europe, the Middle East, Asia, and Australia. We source, headhunt, and discover new and top talent through a targeted approach and search methodology and have a proven track record in sourcing and positioning exceptional candidates into our client's organizations in any mining discipline or level. Mining International provides a transparent, informative, and trusted consultancy service to our candidates and clients to help them develop their careers and business goals and objectives in this ever-changing marketplace. Podcast Description Rob Tyson is an established recruiter in the mining and quarrying sector and decided to produce the “Dig Deep” The Mining Podcast to provide valuable and informative content around the mining industry. He has a passion and desire to promote the industry and the podcast aims to offer the mining community an insight into people's experiences and careers covering any mining discipline, giving the listeners helpful advice and guidance on industry topics. See omnystudio.com/listener for privacy information.

Kill them all! When it comes to oral health, outdated technology and science has convinced us that our goal is to KILL THEM ALL! Or at least 99.99% right? I'm talking about bacteria. We all grew up with ads and products targeted towards annihilating bacteria. But honestly, that science is so outdated. Sterilization has become a way of handling our health, which is a very western way of thinking, and quite intense. We are conditioned to be terrified of bacteria, fungus, etc. But you are walking bacteria! There are so many wonderful solutions to oral health that aren't over-kill. There are products, ingredients (like essential oils), aloe vera, and more that can up your oral health game to a much higher level. I sit down with CBO of the much loved oral-care brand Lumineux, Caroline Duggan, to discuss all things oral health. She may just blow your mind!Learn more about Luminex by visiting their website here, or find them on IG at @lumineuxhealth See full show notes for this episode HERE. Leave us a review while you're there.Lookin' for some podcast goodies? I've got ya covered! Shop our t-shirts, swag, and other popular products HERENew to essential oils? Here is my free guide to help you demystify this topic FREE Essential Oils Guide.Our website is www.RevolutionOilsPodcast.comView hundreds of Essential Oil Recipes in our DIY DugoutSign up for my PODCAST NEWSLETTER and you'll get FREE tips on how to live a healthier, more balanced life! Say hello on social. Use the Hashtag #essentialoilrevolutionpodcast so I know you're a friend!FacebookInstagramGrab yourself a freebie here! ---> https://linktr.ee/samleewrightThank you to our amazing sponsors.Heard about a product you'd like to try? View our list of sponsors HERE and help us keep this podcast 100% free!FAQs:Who is Samantha Lee Wright?Which brand of oils do you recommend and why?Is it safe to ingest essential oils? (And other safety concerns)Are essential oils safe for cats? (See safety section)Hey! Thanks for listening. Send me a message & tell me what you think about the show. Leave a review so others can find the show more easily too.xo,SamSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Epson, es uno de los mayores productores de proyectores en el mundo, esta vez nos sorprendió con sus nuevos proyectores con tecnología 3LCD, con más de 20.000 luminex, denotando lo compacto del equipo y su peso ligero de 25 Kg.

Luminex Senior Vice President of Global Manufacturing and Quality Randy Myers talks about manufacturing COVID-19 tests within the life sciences industry and scaling their manufacturing operations.

Oncotarget published this trending research paper on April 13, 2021, entitled, "Urine protein biomarkers of bladder cancer arising from 16-plex antibody-based screens" conducted by researchers from the University of Houston and UT Southwestern Medical Center. Bladder cancer is four times more common among men than women, and it is the sixth most common cancer diagnosis in the United States. However, researchers have found that cystoscopy—the primary method physicians use to diagnose patients with bladder cancer—is relatively invasive, expensive, and has the potential to cause urinary tract infections. “In contrast, urine is a noninvasive and readily available biological fluid that can be used for diagnostic tests.” Patients may benefit in a number of different ways by using urine as fluid in diagnostic testing for bladder cancer. Urine is readily bioavailable, non-invasive, and it can also be collected and tested on a regular basis. Patients can even use various cost-effective point-of-care diagnostic tools, including at-home testing. First, the researchers assessed whether there were useful biomarkers of bladder cancer to be found in this fluid. The team used Luminex screening to test for both low and high levels of 16 proteins utilizing highly specific antibody-protein interactions. “In this study, Luminex screening was used to simultaneously assay the protein abundances of 16 potential biomarkers in different stages of bladder cancer and then compared to urology clinic controls.” ELISA validation was then used to determine which proteins were significantly elevated in bladder cancer. They found that levels of three urine proteins were capable of distinguishing between control and bladder cancer urine. One protein was also found to be capable of discriminating between high- and low-grade disease, and the successive clinical stages of bladder cancer. “Upon ELISA validation, urine IL-1α, IL-1ra, and IL-8 were able to distinguish control urine from urine drawn from various bladder cancer stages, with IL-8 being the best discriminator.” To date, the research paper has generated an Altmetric Attention Score of 55. The Altmetric Attention Score provides an at-a-glance indication of the volume and type of online attention the research has received. Top Oncotarget publications rated by Altmetric Attention Score - https://www.oncotarget.com/news/altmetric/ Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.27941 DOI - https://doi.org/10.18632/oncotarget.27941 Full text - https://www.oncotarget.com/article/27941/text/ Correspondence to - Chandra Mohan - cmohan@central.uh.edu Keywords - urothelial, proteomics, targeted screens, interleukins, inflammation About Oncotarget Oncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology. To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget YouTube - https://www.youtube.com/c/OncotargetYouTube/ LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Oncotarget is published by Impact Journals, LLC please visit https://www.ImpactJournals.com or connect with @ImpactJrnls Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

❤️ Loved it!👎 Meh…Summary transcript: https://www.listory.com/ll/7f2e4a3c198bdbf1ac436c8cad51c94ba34f379bOriginal story: https://finance.yahoo.com/news/billionaire-israel-englander-bets-2-143857211.htmlDescription: Let's talk about risk, reward, and pennies. The three are related, of course. There's no reward in the stock market without taking on some risk – and penny stocks offer investors an optimum combination of both. The ‘pennies' are the lowest cost stocks on the public markets, typically priced below $5 per share. At such a low share price, even a small gain – a share price increase of mere pennies – can quickly translate into a high-percentage return. However, there is a but here. The critics point out that there could be a reason for the bargain price tag, whether it be poor fundamentals or overpowering headwinds. So, how are investors supposed to determine which penny stocks are poised to make it big? Following the activity of the investing titans is one strategy. Enter Israel “Izzy” Englander, who is widely known for his impressive stock picking abilities. Englander expressed interest in the stock market since he was young, and in 1989, co-founded hedge fund Millennium Management with Ronald Shear. Using a broad range of strategies involving a variety of predominantly liquid asset classes, Englander was able to take the $35 million the fund was started with and turn it into a $45+ billion Wall Street behemoth. With an estimated net worth of $9.6 billion in 2021, it's no wonder Wall Street focus locks in on the guru when he makes a move. Taking all of this into consideration, we used TipRanks' database to take a closer look at two penny stocks Englander snapped up recently. The platform revealed that both Buy-rated tickers have earned the support of some members of the analyst community as well. T2 Biosystems (TTOO) We'll start in the healthcare industry, where T2 Biosystems is working to revolutionize diagnostics. The company offers diagnosticians and medical labs a range of devices based on its T2 Magnetic Resonance (T2MR) tech to quickly and accurately diagnosis a variety of septic illnesses. As the company notes, sepsis claims more lives annually than AIDS, breast cancer, and prostate cancer combined. Rapid and accurate diagnosis is the key for patient survival, and this is the niche that T2 aims to fill. The company's technology enables diagnostic blood tests with results available in a matter of hours, compared to the 1 to 5 days currently taken by most medical lab tests. Available testing products include the T2Bacteria Panel and the T2Candida panel, which are the only FDA-approved blood tests for septic agents that do not need to wait for a blood culture. A T2SARS-CoV-2 Panel is also available, using upper respiratory samples. T2 has an active product pipeline, with rapid diagnostic tests on the drawing board for a variety of illnesses. Upcoming products include the T2Cauris panel and the T2Resistance panel. These testing products are currently designated for research use only (ROU) in the US. The T2Lyme panel, which will allow for faster diagnosis of the difficult-to-determine Lyme disease, is at an earlier stage of the development. All of T2's products operate on the same T2Dx instrument, allowing for interchangeability in the lab environment. The device offers a simple user interface, and operates with just 4ml of whole blood. T2 boasts that its device is in use in more than 200 hospitals worldwide. In the first quarter of 2021, T2 saw top-line revenue grow by 173% year-over-year, to $7 million. This was driven by a 345% yoy increase in product revenue, to $4.7 million. Sepsis test utilization in the US rose by 85% yoy in the quarter, showing increasing acceptance of the device and technology. Izzy Englander is among those that have high hopes for this healthcare name. In Q1, Englander's Millennium picked up over 1.36 million shares of TTOO stock, now valued at $1.5 million. This increased Englander's stake in the company to 2.68 million shares, with a market value of $2.9 million. 5-star analyst Charles Duncan, of Canaccord, also counts himself as a fan. Duncan gives TTOO shares a Buy rating along with a $3.50 price target. This target conveys his confidence in TTOO's ability to soar 212% higher in the next twelve months. (To watch Duncan's track record, click here) “T2's +345% Y/Y product revenue growth is a positive datapoint for the company's post-pandemic commercial strategy, which is being supported by a scaling to just under 10 direct sales reps in Q1. We view the acquisitions of Cepheid, BioFire, GenMark, and Luminex as validation that the hospital lab is an attractive industry segment, given clinicians' (and patients') desire to shift away from centralized testing strategies to a more decentralized approach. With these four companies off the table, T2 should benefit from scarcity value. Separately, a more aggressive approach towards commercial execution should marry well with rising awareness around antimicrobial resistance and sepsis, in a post-pandemic environment that prioritizes infectious disease diagnostics," Duncan noted. It turns out that other analysts also have high hopes. With 4 Buys and a single Hold, the word on the Street is that this stock, which currently going for $1.10 apiece, is a Strong Buy. In addition, the $2.83 average price target puts the upside potential at 156%. (See TTOO stock analysis on TipRanks) Sesen Bio (SESN) The second stock we're looking at, Sesen Bio, is a pharmaceutical company. Sesen works in the cancer treatment segment, developing antibody-drug conjugate therapies. The program takes a fusion protein approach, tethering tumor-targeting antibodies to cytotoxic proteins. The result is a single protein molecule that kills cancer cells with minimal toxic effects on the body – and that generates a complementary response from the patient's natural immune system. Sesen's pipeline currently includes one drug candidate, vicineum, which is under investigation on several tracks concurrently. The main track, which has completed clinical trials and initiated the submission process of the biologic license application (BLA), is for the treatment of non-muscle invasive bladder cancer. The BLA was accepted for filing by the FDA this past February, and the company is on track for potential approval on August 18, 2021. European approval of vicineum for bladder cancer treatment is expected early in 2022. The company's other pipeline projects are at earlier stages. Vicineum is under investigation as a treatment for head and neck cancers, and is in Phase 2 trials. Other investigative tracks remain at pre-clinical stages. Clinical-stage biopharma companies are always highly speculative, and in this case, Englander did not mind speculating. In Q1, his firm bought 987,926 shares of SESN, increasing its stake in the company by 156%. Englander's holding in Sesen is now valued at $2.9 million. Weighing in on SESN for H.C. Wainwright, 5-star analyst Swayampakula Ramakanth sees an opportunity as well. "Given the favorable risk/benefit profile of Vicineum demonstrated in the Phase 3 VISTA study, we believe the drug has a high likelihood to receive regulatory approvals from the FDA and EMA. Sesen is actively preparing for the potential launch of Vicineum. The company has selected Syneos, a leading contract sales organization, as a partnerto build and manage a 35-people sales force to target approximately 2,000 high prescribers of BCG. We expect the drug to be commercially available immediately upon approval. We project Vicineum to achieve risk-adjusted sales of $516M by 2030E, growing from $9M in 2021E," Ramakanth opined. Ramakanth's comments support his Buy rating on the stock, as does his $8 price target. At current valuations, that target implies an upside potential of 170% for the next 12 months. (To watch Ramakanth's track record, click here) Sometimes, the penny stocks can slide under the radar; this one has attracted only two recent analyst reviews. Both agree, however, that this is a stock to buy, making the Moderate Buy consensus unanimous. The shares are priced at $2.94 with a $7.50 average price target that suggests an upside of 155% in the coming year. (See SESN stock analysis on TipRanks) To find good ideas for penny stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a newly launched tool that unites all of TipRanks' equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

Priorità gli ultraottantenni per i quali si guarda a una messa in sicurezza entro aprile. Spazio poi alle persone con elevata fragilità, familiari conviventi e i caregiver e subito dopo i 70-79 anni e tra 60-69 anni, a cui va prevalentemente il vaccino Astrazeneca. Accanto a loro, in parallelo, va terminata la vaccinazione dei sanitari, ma solo quelli «in prima linea nella diagnosi, nel trattamento e nella cura» della malattia e coloro che operano in presenza presso strutture sanitarie e sociosanitarie pubbliche e private. I criteri ridisegnati dal commissario per l'Emergenza Figliuolo bloccano la vaccinazione del personale scolastico, delle forze armate e delle forze di polizia, tranne che per chi ha avuto la prima dose che potrà completare il ciclo. Stop anche alle somministrazioni nelle carceri, salvo over 60 o fragili. Stop, per ora, al programma per rendere le isole Covid free. Covid e vaccini, Regioni in ordine sparso Durante la gestione della pandemia erano già emersi i limiti di avere sistemi sanitari affidati alle Regioni e la conferma si è avuta anche dall'inizio della campagna vaccinale. Com'è possibile che il Molise, regione oggi più virtuosa nella somministrazione delle dosi, abbia somministrato dosi (tra prima e seconda) pari al 27,21% della popolazione residente, dieci punti percentuali in più rispetto alla Calabria, ultima in classifica con il 17,75%.Queste differenze emergono anche quando si va a vedere la distribuzione per classe di età: la Provincia autonoma di Trento ha somministrato la prima dose all'86% degli over-80 e la Sicilia al 45,4%. Le Regioni procedono in ordine sparso, nonostante più volte il governo abbia fatto appello all'unità. Imprese che si rimboccano le maniche Il caso di oggi è Tabui è un'applicazione per la scoperta turistica del territorio. Tramite la realtà aumentata e la geolocalizzazione consente di scoprire tutti i punti di interesse del territorio che si vuole visitare. Dietro la notizia Di ieri sera è la notizia dell'acquisizione della statunitense Luminex da parte dell'azienda italiana della diagnostica Diasorin, per un valore complessivo di 1,8 miliardi di dollari. Luminex sviluppa, produce e vende tecnologie proprietarie e prodotti per esami biologici con varie applicazioni nei settori della diagnostica e del life science. L'operazione verrà finanziata attraverso un mix di cassa e debito: al riguardo, DiaSorin ha firmato una linea con un sindacato di banche che prevede un term loan di 1,1 miliardi di dollari con scadenza nel 2026 e un bridge loan di altri 500 milioni con scadenza entro 12 mesi. A seguito dell'operazione il leverage ratio è stimato in circa 2,5 volte. Il closing è atteso entro il terzo trimestre dell anno. Oggi c'è stata anche la notizia dell'acquisizione di Nuance da parte di Microsoft, per un valore di 19,7 miliardi di dollari. Ospiti: Marzio Bartoloni, Sole 24 Ore, Gilberto Turati, docente di Scienze delle Finanze Università Cattolica del Sacro Cuore, Giorgio Proglio, amministratore delegato di Tabui, Alessandro Plateroti, editorialista Sole 24 Ore.

Hour 1 * Guest: Lowell Nelson – CampaignForLiberty.org – RonPaulInstitute.org. * Domestic Enemies – Ron Paul. * Save the Filibuster. * When Fascism Comes, It Will Be Wearing a Mask – Ron Paul. * SARS-CoV-2 Has Not Been Proven to Exist: The Shocking Research of Christine Massey – Jon Rappoport. 46 institutions have responded to her requests. And none (zero) have indicated that SARS-CoV-2 has been isolated. Isolated means “separated from other material,” which means we actually found the virus and could identify it. “Actual isolation means the virus exists. Inability to isolate it means there is no proof the virus exists.” * How a Retrovirus is Isolated. * COVID: If There Is No Virus, Why Are People Dying? * Deep Flaws of PCR Testing – Gary G. Kohls. We don’t recommend that anyone get tested for Covid, but if you do get a PCR test, then insist on knowing how many cycles were used in your test, and who manufactured your test. * The Swiss Policy Research says “if a person gets a ‘positive’ PCR test result at a cycle threshold (Ct) of 35 or higher the chance that the person is infectious is less than 3%. The chance that the person received a “false positive” result is 97% or higher.” * In the US, a PCR test kit from Quest uses 50 cycles; Inbios test kits use 45 cycles; Luminex, 45 cycles; Gnomegen, 39 cycles; and ThermoFisher, 37 cycles. * The Checkmating of America (Destruction of the Middle Class) – Cherie Zaslawsky. The globalists “have weakened America nearly to the point of no return, by wiping out at least half of our small businesses or more, which means they’ve decimated our once thriving middle class. Hour 2 * Guest: Dr. Scott Bradley – To Preserve The Nation – FreedomsRisingSun.com. * GameStop short squeeze – A Huge Lie, Con Game! * How ex-JP Morgan silver trader’s guilty plea could boost manipulation claim against bank – CnBC.com 2013 Article. * What Was the Year of Jubilee? * The globalists launch a worldwide “Great Reset.”! – AKA Operation Satanic Jubilee! * Mask mandate: Biden signs order requiring masks for US. --- Support this podcast: https://anchor.fm/loving-liberty/support

* Guest: Lowell Nelson - CampaignForLiberty.org - RonPaulInstitute.org. * Domestic Enemies - Ron Paul. * Save the Filibuster. * When Fascism Comes, It Will Be Wearing a Mask - Ron Paul. * SARS-CoV-2 Has Not Been Proven to Exist: The Shocking Research of Christine Massey - Jon Rappoport. 46 institutions have responded to her requests. And none (zero) have indicated that SARS-CoV-2 has been isolated. Isolated means "separated from other material," which means we actually found the virus and could identify it. "Actual isolation means the virus exists. Inability to isolate it means there is no proof the virus exists." * How a Retrovirus is Isolated. * COVID: If There Is No Virus, Why Are People Dying? * Deep Flaws of PCR Testing - Gary G. Kohls. We don't recommend that anyone get tested for Covid, but if you do get a PCR test, then insist on knowing how many cycles were used in your test, and who manufactured your test. * The Swiss Policy Research says "if a person gets a ‘positive’ PCR test result at a cycle threshold (Ct) of 35 or higher the chance that the person is infectious is less than 3%. The chance that the person received a “false positive” result is 97% or higher." * In the US, a PCR test kit from Quest uses 50 cycles; Inbios test kits use 45 cycles; Luminex, 45 cycles; Gnomegen, 39 cycles; and ThermoFisher, 37 cycles. * The Checkmating of America (Destruction of the Middle Class) - Cherie Zaslawsky. The globalists "have weakened America nearly to the point of no return, by wiping out at least half of our small businesses or more, which means they’ve decimated our once thriving middle class.

CM Life Science's Business Consultant, Nathan Rigby, hosts as we welcome CJ Harris to the CM Conversations podcast. CJ is a champion of diversity and inclusion. She has a wealth of experience in the life science sector, currently working as leader of the talent acquisition and learning development team at Luminex Corporation. Luminex is a biotechnology company which develops, manufactures and markets proprietary biological testing technologies with applications in life sciences. Thanks to CJ, it also has a forward-thinking recruitment strategy that embraces diversity and inclusion. We wanted to find out about the successes and challenges CJ has experienced, building diverse and inclusive teams in the life science arena. If you'd like to speak to us about the podcast, please email cmconversation@charltonmorris.com.

In part two of this special episode, you'll hear about Madelyn's work-in-progress, "The Luminex." We'll get into how the story has evolved over the years, the main cast, and the worldbuilding. We hope you've enjoyed this special set of episodes!

In this interview, Luminex CEO Marshall Koval and Senior VP Exploration Leo Hathaway provide a company update and explain why their massive Cascas gold-copper target so prospective. Luminex will begin drilling the Cascas project in late 2020 or early 2021. Marshall also shares an update on the company’s 5M+ AuOz Condor project as well as its two joint-venture projects with BHP and Anglo-American. Marshall said that in H1 of 2021 Luminex should be producing drill results on up to four different projects. 0:00 Introduction 1:15 Cascas gold-copper porphyry target 3:40 Preparing to drill Cascas 5:15 Condor 5M+ AuOz project update 6:43 Lumina Group exit strategy 7:44 Four projects with drill results in H2 2021 9:01 Tarqui and Pegasus A & B updates 10:19 Treasury and burn rate https://luminexresources.com/ TSXV:LR OTC:LUMIF Luminex presentation: https://luminexresources.com/site/assets/files/5470/luminexres_oct27_2020.pdf Most recent press release about the Cascas target: https://luminexresources.com/site/assets/files/5480/nr20-13_oct_22_luminex_discovers_attractive_copper_porp.pdf Sign up for our free newsletter and receive interview transcripts, stock profiles and investment ideas: http://eepurl.com/cHxJ39 Luminex Resources is an MSE sponsor. The forward-looking statement found in Luminex’s most-recent presentation applies to the content of this interview. The content found on MiningStockEducation.com is for informational purposes only and is not to be considered personal legal or investment advice or a recommendation to buy or sell securities or any other product. It is based on opinions, SEC filings, current events, press releases and interviews but is not infallible. It may contain errors and MiningStockEducation.com offers no inferred or explicit warranty as to the accuracy of the information presented. If personal advice is needed, consult a qualified legal, tax or investment professional. Do not base any investment decision on the information contained on MiningStockEducation.com or our videos. We may hold equity positions in and/or be compensated by some of the companies featured on this site and therefore are biased and hold an obvious conflict of interest. MiningStockEducation.com may provide website addresses or links to websites and we disclaim any responsibility for the content of any such other websites. The information you find on MiningStockEducation.com is to be used at your own risk. By reading MiningStockEducation.com, you agree to hold MiningStockEducation.com, its owner, associates, sponsors, affiliates, and partners harmless and to completely release them from any and all liabilities due to any and all losses, damages, or injuries (financial or otherwise) that may be incurred.

We sat down with Marshall Koval (CEO) and Scott Hicks ( VP - Corp Dev) of Luminex Resources (sponsor) to get updated on the company's latest developments. While the world has many issues and challenges ahead, Luminex is moving full steam ahead. Their joint ventures with BHP and Anglo American are progressing well, with new drill targets identified and preparations taking place. Shareholders have been waiting patiently knowing that there investment will pay off big time. Drill results at the Condor Project just came in and they point to an even more richer resource. Luminex is currently hitting it's stride and all shareholders will likely soon be grateful.  www.LuminexResources.com Stock Symbols - TSX.V: LR - OTCQX: LUMF  

We sat down with Marshall Koval (CEO) and Scott Hicks ( VP - Corp Dev) of Luminex Resources (sponsor) to get updated on the company's latest developments. While the world has many issues and challenges ahead, Luminex is moving full steam ahead. Their joint ventures with BHP and Anglo American are progressing well, with new drill targets identified and preparations taking place. Shareholders have been waiting patiently knowing that there investment will pay off big time. Drill results at the Condor Project just came in and they point to an even more richer resource. Luminex is currently hitting it's stride and all shareholders will likely soon be grateful.  www.LuminexResources.com Stock Symbols - TSX.V: LR - OTCQX: LUMF  

In this interview, Luminex President Diego Benalcazar and CEO Marshall Koval provide a company update and explain why their Cascas gold-copper target so prospective. Luminex will begin drilling the Cascas project in late 2020 or early 2021. Diego explains that the company is currently building the onsite camp after having developed a strong relationship with the local community. Marshall elaborates on the excellent, recent drill and metallurgical results from the Condor project (5M gold oz). Marshall also recaps the upcoming catalysts for Luminex as the company hopes to have four projects with drill rigs turning before year-end. 0:00 Introduction 1:40 Potential of Cascas large gold-copper project 5:10 Why has Cascas not been drilled yet? 6:16 Gaining trust of locals prior to drilling Cascas 8:51 Cascas drill permits 9:59 Accessing Cascas and building the camp 10:54 Balancing greenfield and advanced-stage projects 13:41 How many drills will Luminex have running? 14:05 Excellent drill results at Condor project 15:28 Positive metallurgical results at Condor project 18:28 Balancing Condor’s expansion drilling and engineering work https://luminexresources.com/ TSXV:LR OTC:LUMIF Sign up for our free newsletter and receive interview transcripts, stock profiles and investment ideas: http://eepurl.com/cHxJ39 Luminex Resources is an MSE sponsor. The forward-looking statement found in Luminex’s most-recent presentation applies to the content of this interview. The content found on MiningStockEducation.com is for informational purposes only and is not to be considered personal legal or investment advice or a recommendation to buy or sell securities or any other product. It is based on opinions, SEC filings, current events, press releases and interviews but is not infallible. It may contain errors and MiningStockEducation.com offers no inferred or explicit warranty as to the accuracy of the information presented. If personal advice is needed, consult a qualified legal, tax or investment professional. Do not base any investment decision on the information contained on MiningStockEducation.com or our videos. We may hold equity positions in and/or be compensated by some of the companies featured on this site and therefore are biased and hold an obvious conflict of interest. MiningStockEducation.com may provide website addresses or links to websites and we disclaim any responsibility for the content of any such other websites. The information you find on MiningStockEducation.com is to be used at your own risk. By reading MiningStockEducation.com, you agree to hold MiningStockEducation.com, its owner, associates, sponsors, affiliates, and partners harmless and to completely release them from any and all liabilities due to any and all losses, damages, or injuries (financial or otherwise) that may be incurred.

In this episode, Jonathan Clark, CEO of Luminex, talks with us about Luminex’s platform for institutional equities block trading. We discuss the new work-from-home environment, how it has impacted buy side equities traders, and how Luminex has leveraged OpenFin to transform end-user trading experiences.

Ross Beaty has a habit of being in the right place at exactly the right time.  In 2013 Beaty and his group perceived that in an effort to offset declining petroleum revenues, the Ecuadorian government was on the verge of liberalizing archaic mining laws and letting out extremely promising unexplored concessions.   In 2018, predecessor company Lumina Gold was awarded 32 mining concessions. 2019 was a milestone year, which saw large scale projects Fruta Del Norte and Mirador come on line.                The Company currently has 3 key assets and 2 world class partners: Condor which it is exploring iselft; and two separate earn-in agreements with BHP and Anglo American on its Tarqui, and Pegaus A&B concessions. Luminex also holds several other early-stage Ecuadorian exploration concessions. In mining, management is always the key to increasing shareholder value. However, Luminex has something else that few if any mining concerns possess, long-term loyal committed   management. CEO Marshall Koval and SVP of Exploration Leo Hathaway have been working together since 2004 on a number of the Lumina Group's projects. During this time, they've helped return over $1.6 billion to shareholders and judging from this interview they have many more successes ahead of them. It's always a good idea to bet on the winners.  Company website: www.Luminexresources.com Stock Ticker Symbols: TSX.V LR OTC:LUMIF           

Ross Beaty has a habit of being in the right place at exactly the right time.  In 2013 Beaty and his group perceived that in an effort to offset declining petroleum revenues, the Ecuadorian government was on the verge of liberalizing archaic mining laws and letting out extremely promising unexplored concessions.   In 2018, predecessor company Lumina Gold was awarded 32 mining concessions. 2019 was a milestone year, which saw large scale projects Fruta Del Norte and Mirador come on line.                The Company currently has 3 key assets and 2 world class partners: Condor which it is exploring iselft; and two separate earn-in agreements with BHP and Anglo American on its Tarqui, and Pegaus A&B concessions. Luminex also holds several other early-stage Ecuadorian exploration concessions. In mining, management is always the key to increasing shareholder value. However, Luminex has something else that few if any mining concerns possess, long-term loyal committed   management. CEO Marshall Koval and SVP of Exploration Leo Hathaway have been working together since 2004 on a number of the Lumina Group's projects. During this time, they've helped return over $1.6 billion to shareholders and judging from this interview they have many more successes ahead of them. It's always a good idea to bet on the winners.  Company website: www.Luminexresources.com Stock Ticker Symbols: TSX.V LR OTC:LUMIF           

Luminex Resources shared new drill results from the Condor Camp deposit in Ecuador. Probe Metals shared an exploration update. Rio Tino looking to acquire an interest in Midnight Sun's Solwezi Licenses. Northern Vertex shared production results. Torex's open-pit at El Limon Guajes close to depletion. We'd like to thank our Sponsors! Integra Resources trades on the TSX-V under ITR and the OTCQX under IRRZF. Integra Resource is advancing its past producing DeLamar Gold-Silver project in SW Idaho through aggressive drilling and exploration. The latest Resources Estimate released earlier this summer showed approximately 4 million Gold equivalent ounces in the measured and indicated category.The maiden PEA for the project established a net present value of C$473-million and an IRR of 43%. The management of Integra successfully sold its previous brownfields project for C$590 million in summer 2017. Read more about the company and its successful management team at integraresources.com. Corvus Gold is an advanced gold-silver exploration and development company focused on the North Bullfrog and Mother Lode Projects in Nevada. The company has been named a Top Five TSX gold equity performer Four of the last Seven years & a multi time top 50 OTCQX performer. Corvus Gold trades on the Toronto Stock Exchange with the symbol KOR and on the OTCQX with CORVF. Follow all the news form Corvus and its two-mine projects with fast-tracked potential via the company's website, corvusgold.com. Western Copper and Gold is focused on developing the world-class Casino project in Canada's Yukon Territory. The Casino project consists of an impressive 10 billion pounds of copper and 18 million ounces of gold in an overall resource. Western Copper and Gold trades on the TSX and the NYSE American with WRN. Be sure to follow the company via their website, www.westerncopperandgold.com.

A) Jon discusses his background and transition: 1- There is a stereotypical path, a skill path, and path that you may want (You define your path) 2- Side Hustles can buy you time to decided and learn career choices 3- Importance of having a plan, taking your time, and having an end state 4- Importance of Networking (Build your Linked, have coffee, play golf, listen, and don't be bashful- You own it!) B) Who is Luminex?  What do they do?  What do they value? C) Military Skills that translated 1- Project / Program Management 2- Conceptual Problem Solving 3- Team Work 4- Resource Management 5- Organizational Skills (Structured, Time Management) 6- Data Analysis D) What skills Needed to be learned and how 1- Learning how the industry works  2- Learning Industry Standards 3- Learning Excel 4- Learning Supply Chain Management 5- Learning Inventory Management ***Learn from mentors, co-workers, OJT, and realize you will not get fired if you make a mistake E) Other discussion points 1- Be Continuous Learner 2- Jobs can set you back, so have a plan and do not just say yes for income purposes 3- Importance of Assessing your potential employer 4- How to generate interview questions and the importance of company research 5- Comparison of Large and Small Companies F) Parting Wisdom ***Be prepared to adjustments, stress, adversity, change, making mistakes and wrong decisions...it is part of the processes.  Stay positive! References: https://www.linkedin.com/in/jonathan-wilson-89b9a418/ --- Send in a voice message: https://anchor.fm/viewfromtheskies/message Support this podcast: https://anchor.fm/viewfromtheskies/support

Jane Ferguson:                  Hi there. Welcome to Getting Personal: Omics of the Heart, the podcast from Circulation: Genomic and Precision Medicine. I'm Jane Ferguson, and this is Episode 36 from February 2020.                                                 First up, we have “Identification of Circulating Proteins Associated with Blood Pressure Using Mendelian Randomization” from Sébastien Thériault, Guillaume Paré, and colleagues from McMaster University in Ontario. They set out to assess whether they could identify protein biomarkers of hypertension using a Mendelian randomization approach. They analyzed data from a genome-wide association study of 227 biomarkers which were profiled on a custom Luminex-based platform in over 4,000 diabetic or prediabetic participants of the origin trial.                                                 They constructed genetic predictors of each protein and then used these as instruments for Mendelian randomization. They obtained systolic and diastolic blood pressure measurements in almost 70,000 individuals, in addition to mean arterial pressure and pulse pressure in over 74,000 individuals, all European ancestry with GWAS data, as part of the International Consortium for Blood Pressure.                                                 Out of the 227 biomarkers tested, six of them were significantly associated with blood pressure traits by Mendelian randomization after correction for multiple testing. These included known biomarkers such as NT-proBNP, but also novel associations including urokinase-type plasminogen activator, adrenomedullin, interleukin-16, cellular fibronectin and insulin-like growth factor binding protein-3. They validated all of the associations apart from IL-16 in over 300,000 participants in UK Biobank. They probed associations with other cardiovascular risk markers and found that NT-proBNP associated with large artery atherosclerotic stroke, IGFBP3 associated with diabetes, and CFN associated with body mass index.                                                 This study identified novel biomarkers of blood pressure, which may be causal in hypertension. Further study of the underlying mechanisms is required to understand whether these could be useful therapeutic targets in hypertensive disease.                                                 The next paper comes from Sony Tuteja, Dan Rader, Jay Giri and colleagues from the University of Pennsylvania and it's entitled, “Prospective CYP2C19 Genotyping to Guide Antiplatelet Therapy Following Percutaneous Coronary Intervention: A Pragmatic Randomized Clinical Trial”.                                                 They designed a pharmacode genomic trial to assess effects of CYP2C19 genotyping on antiplatelet therapy following PCI. Because loss of function alleles in CYP2C19 impair the effectiveness of clopidogrel, the team were interested in understanding whether knowledge of genotype status would affect prescribing in a clinical setting. They randomized 504 participants to genotype guided or usual care groups and assessed the rate of prasugrel or ticagrelor prescribing in place of clopidogrel within each arm. As a secondary outcome, they assessed whether prescribers adhere to genotype guided recommendations. Of genotyped individuals, 28% carried loss of function alleles. Within the genotype guided group overall, there was higher use of prasugrel or ticagrelor with these being prescribed to 30% of patients compared with only 21% in the usual care group. Within genotype individuals carrying loss of function alleles, 53% were started on prasugrel or ticagrelor, demonstrating some adherence to genotype guided recommendations.                                                 However, this also meant that 47% of people whose genotype suggested reduced effectiveness were nevertheless prescribed clopidogrel. This study highlights that even when genotype information is available, interventional cardiologists consider clinical factors such as disease presentation and may weight these more highly than genotype information when selecting antiplatelet therapy following PCI.                                                 The next paper is about “Deep Mutational Scan of an SCN5A Voltage Sensor and comes to us from Andrew Glazer, Dan Roden and colleagues from Vanderbilt University Medical Center. In this paper, the team aim to characterize the functional consequences of variants and the S4 voltage sensor of domain IV and the SCN5A gene using a high throughput method that they developed. SCN5A encodes the major voltage gated sodium channel in the heart and variants in SCN5A can cause multiple distinct genetic arrhythmia syndromes, including Brugada syndrome, long QT syndrome, atrial fibrillation, and dilated cardiomyopathy, and have been linked to sudden cardiac death.                                                 Because of this, there's considerable interest in understanding the functional and clinical consequences of different variants, but previous approaches were time consuming and results were often inconclusive with many variants being classified as uncertain significance. This newly developed deep mutational scanning approach allows for simultaneous assessment of the function of thousands of variants, making it much more efficient than low throughput patch clamping. The team assessed the function of 248 variants using a triple drug assay in HEK293T cells expressing each variant and they identified 40 putative gain of function and 33 putative loss of function variants. They successfully validated eight of nine of these by patch clamping data. Their study highlights the effectiveness of this deep mutational scanning approach for investigating variants in the cardiac sodium channel SCN5A gene and suggests that this may also be an effective approach for investigating putative disease variants and other ion channels.                                                 The next article is a research letter from Connor Emdin, Amit Khera, and colleagues from Mass General Hospital in the Broad Institute entitled, “Genome-Wide Polygenic Score and Cardiovascular Outcomes with Evacetrapib in Patients with High-Risk Vascular Disease: A Nested Case-Control Study”. In this study, the team set out to probe the utility of using polygenic risk scores to predict the risk of major adverse cardiovascular events within individuals already known to be at high cardiovascular risk and to assess whether genetic scores can identify individuals who would benefit from the use of a CETP inhibitor such as Evacetrapib. They analyze data from the ACCELERATE trial which had tested Evacetrapib in a high risk population, and they found no effect on the incidents of major adverse cardiovascular events overall. Within a nested case-control sample of individuals experiencing major CVD events versus no events, they applied a polygenic risk score and found that the score predicted major cardiovascular events.                                                 Patients in the highest quintile of the risk score were at 60% higher risk of a major cardiovascular event than patients in the lowest quintile. There was no evidence of any interaction between the genetic risk score and Evacetrapib. These data suggest that genetic risk scores may have utility in identifying individuals at high risk events but may not have utility in identifying individuals who may derive more benefit from CETP inhibition. The next letter concerns “Epigenome-Wide Association Study Identifies a Novel DNA Methylation in Patients with Severe Aortic Valve Stenosis” and comes from Takahito Nasu, Mamoru Satoh, Makoto Sasaki and colleagues from Iwate Medical University in Japan. They were interested in understanding whether differences in DNA methylation could underlie the risk of aortic valve stenosis. They conducted an EWAS or epigenome-wide association study of peripheral blood mononuclear cells or PBMCs from 44 individuals with aortic stenosis and 44 disease free controls.                                                 They collected samples at baseline before a surgical intervention in the individuals with aortic stenosis and collected a follow-up sample one year later. They found that DNA methylation at a site on chromosome eight mapping to the TRIB1, or tribbles homolog one gene, was lower in the aortic stenosis group than in the controls at baseline. They replicated the association in an independent sample of 50 cases and 50 controls. TRIB1 MRNA levels were higher in the aortic stenosis group than the controls. When they looked at methylation status one year after aortic valve replacement or a transcatheter aortic valve implantation in patients with stenosis, they found that DNA methylation had increased in the cases while TRIB1 MRNA decreased. These data suggests that methylation status of TRIB1 and expression of TRIB1 may relate to the disease processes in aortic stenosis such as hemodynamic dysregulation and they can be reversed through surgical intervention. Changes in the methylation status of TRIB1 could be a novel biomarker of response to aortic valve replacement.                                                 The next letter comes from Niels Grote Beverborg, Pim van der Harst, and colleagues from University Medical Center Groningen and is entitled, “Genetically Determined High Levels of Iron Parameters Are Protective for Coronary Artery Disease”. Their study addresses the conflicting hypotheses that high iron status is either deleterious or protective against cardiovascular disease. The team constructed genetic predictors of serum iron status using 11 previously identified snips and tested the genetic association with CAD in UK Biobank data from over 408,000 white participants. Overall, the genetic score for higher iron status was associated with protection against CAD. Ten of the snips suggested individual neutral or protective effects of higher iron status on CAD, while one iron increasing snip was associated with increased risk of disease but this was thought to be likely through an iron independent mechanism. Overall, these data suggest that a genetic predisposition to higher iron status does not increase risk of CAD and is actually protective against disease.                                                 The final letter is entitled, “Confidence Weighting for Robust Automated Measurements of Popliteal Vessel Wall MRI” and comes from Daniel Hippe, Jenq-Neng Hwang, and colleagues from the University of Washington. They were interested in assessing whether images of popliteal artery wall incidentally obtained during knee MRI as part of an osteoarthritis study could be used to study the development and progression of atherosclerosis. They developed an automated deep learning based algorithm to segment and quantify the popliteal artery wall in images obtained over 10 years in over 4,700 individuals. Their approach, which they named FRAPPE, or fully automated and robust analysis technique for popliteal artery evaluation, was able to reduce the average time required for segmentation analysis from four hours to eight minutes per image. They applied weights based on confidence for each segment to automatically improve the accuracy of aggregate measurements such as mean wall thickness or mean lumen area. Their data suggest that this automated method can rapidly generate useful information on atherosclerosis from MRI images obtained as part of other studies. When combined with other data. This approach may facilitate novel discovery in secondary analyses of existing studies in an efficient and cost effective way.                                                 And that's all for issue one of 2020. Come back next time for more of the latest papers from Circulation: Genomic and Precision Medicine. Speaker 2:                           This podcast is copyright American Heart Association 2020.  

Luminex is exploring and advancing its now 5+ million ounce Condor gold project as well as enjoying the benefit of having BHP and Anglo American create value for shareholders by spending up to US$100M on its projects through earn-in agreements. At Luminex’s current market cap of only about US$35M, CEO Marshall Koval stated: “every CEO will tell you their share price, and their stock, and their company is well undervalued. I'm telling you that we're super undervalued here and it's a great investment opportunity.” In this interview Marshall elaborates on why Luminex is undervalued and Senior VP of Exploration Leo Hathaway provides a geological update on the Condor gold project and why the company expects the resource to continue to grow. Mining entrepreneur Ross Beaty owns 19.9% of Luminex Resources and stated in a recent MSE interview: “you’ve got so many shots of big, big value creators in this company, it was a very easy thing for me to participate in. And I think I’m now the largest shareholder at 20%. I would buy the stock every day if I could. It’s just a really, really great exploration speculation with multiple assets, any one of which could give you a multiple of where the stock is trading at today. So it’s cheap, well-managed. It’s got enough capital to follow its business plan for the year. Those are all things, the things I look for in an excellent speculation and Lumina Gold has that in spades. Luminex has that I would say even more. So that’s why I’m an investor.” 0:15 Introduction 2:15 Luminex provides investors with multiple value-creating projects 5:37 Condor gold project is now over 5+M AuOz (6M AuEqOz) 7:51 Condor gold project has tremendous further discovery potential 9:22 Condor’s potential to become a tier-one gold project? 13:36 Navigating Luminex forward amid the COVID-19 crisis 15:54 Further expanding upon Condor’s future discovery potential 19:30 Anglo spending US$57.3M to advance Pegasus A&B projects 21:52 BHP spending US$42M to advance Tarqui copper project News Releases discussed in this interview: http://www.miningstockeducation.com/2020/03/luminex-discovers-new-high-grade-area-at-the-camp-zone-including-28-1-metres-true-thickness-of-3-1-g-t-gold-and-68-2-g-t-silver-and-provides-an-exploration-update-on-pegasus-ab/ http://www.miningstockeducation.com/2020/03/luminex-announces-maiden-camp-deposit-inferred-mineral-resource-estimate-of-0-9-million-ounces-gold-and-updates-condor-mineral-resource-estimate/ https://luminexresources.com/ TSXV:LR OTC:LUMIF Sign up for Luminex’s email list: https://luminexresources.com/contact/contact-us/ Sign up for our free newsletter and receive interview transcripts, stock profiles and investment ideas: http://eepurl.com/cHxJ39 Luminex Resources is an MSE sponsor. The forward-looking statement found in Luminex’s most-recent presentation applies to the content of this interview. The content found on MiningStockEducation.com is for informational purposes only and is not to be considered personal legal or investment advice or a recommendation to buy or sell securities or any other product. Please visit our website for our full disclaimer.

Mining entrepreneur Ross Beaty believes it is an excellent time to invest in gold and gold equities. In this interview, Ross stated: “it's obviously a fabulous buying opportunity right now, especially anything with gold attached to it. Because gold has such fabulous fundamentals today. Probably the best that I've seen in my entire career….People are going to put some of their money into gold as a long-term store of value and its price will go up. So anything with gold in it is likely to be good.” In addition to providing commentary on the recent sell-off and volatility in the gold stocks, Ross specifically shares why he has invested in Lumina Gold and its spin-out company Luminex Resources: “you've got so many shots of big, big value creators in this company, it was a very easy thing for me to participate in. And I think I'm now the largest shareholder at 20%. I would buy the stock every day if I could. It's just a really, really great exploration speculation with multiple assets, any one of which could give you a multiple of where the stock is trading that today. So it's cheap, well-managed. It's got enough capital to follow its business plan for the year. Those are all things, the things I look for in an excellent speculation and Lumina Gold has that in spades. Luminex has that I would say even more. So that's why I'm an investor.” Ross Beaty is a geologist and resource entrepreneur with over 45 years of experience in the international minerals and renewable energy industries. He is an internationally recognized leader in both non-renewable and renewable resource development, having founded and divested several companies. In addition to Pan American Silver, Ross is the Chairman of Equinox Gold Corp., a mid-tier gold producer. 0:15 Introduction 2:39 Why Ross invested in Lumina Gold & Luminex Resources 7:33 Selling Lumina Gold’s 17M AuOz Cangrejos deposit 10:40 Handling recent extreme volatility in mining stocks 13:23 COVID-19 crisis and long-term disruption to mining? 15:35 Base metal outlook 17:02 Silver outlook 19:02 Genesis of Pan American Silver 20:48 Mistakes to avoid in this mining bull market 23:36 Characteristics of a stellar mining entrepreneur 26:04 Are ESG issues stressed too much in Western culture? 28:06 Final advice Show sponsor: https://luminexresources.com/ TSXV:LR OTC:LUMIF Luminex news release mentioned: https://luminexresources.com/site/assets/files/5412/2020-03-24-nr-lr-rt89nbf11q.pdf Sign up for our free newsletter and receive interview transcripts, stock profiles and investment ideas: http://eepurl.com/cHxJ39 The content found on MiningStockEducation.com is for informational purposes only and is not to be considered personal legal or investment advice or a recommendation to buy or sell securities or any other product. It is based on opinions, SEC filings, current events, press releases and interviews but is not infallible. It may contain errors and MiningStockEducation.com offers no inferred or explicit warranty as to the accuracy of the information presented. If personal advice is needed, consult a qualified legal, tax or investment professional. Do not base any investment decision on the information contained on MiningStockEducation.com or our videos. We may hold equity positions in some of the companies featured on this site and therefore are biased and hold an obvious conflict of interest. MiningStockEducation.com may provide website addresses or links to websites and we disclaim any responsibility for the content of any such other websites. The information you find on MiningStockEducation.com is to be used at your own risk. By reading MiningStockEducation.com, you agree to hold MiningStockEducation.com, its owner, associates, sponsors, affiliates, and partners harmless and to completely release them from any and all liabilities due to any and all losses, damages, or injuries (financial or otherwise) that may be incurred.

Tim and Jonathan walk through the action-packed 20+ years that led to the creation of BIDS and Luminex – two alternative trading systems that specialize in large block trading.

Mining entrepreneur Ross Beaty owns 19.9% of Luminex Resources which is a spin-out of Lumina Gold Corp. In this interview, Luminex CEO Marshall Koval provides an overview of Luminex’s investment value proposition and why he believes the company is currently undervalued. Luminex is exploring and advancing its 4M ounce Condor gold deposit as well as enjoying the benefit of having BHP and Anglo American create value for shareholders by spending up to US$100M on its projects through earn-in agreements. 0:15 Introduction 3:08 Lumina Group’s rationale for having same managers over multiple companies 6:17 Discussing Ecuador as a mining jurisdiction 10:25 Condor 4M gold oz deposit but only C$44M market cap? 12:38 Condor project overview and upcoming catalysts 15:01 More sunk costs spent on Condor than current Luminex market cap 17:36 Condor project burn rate 18:00 Luminex owns 90% of Condor project 19:20 Moving Condor project forward in 2020 20:37 BHP and Anglo American committed up to US$100M to explore Luminex projects 23:05 Recapping reasons to invest in Luminex Resources https://luminexresources.com/ TSXV:LR OTC:LUMIF Sign up for our free newsletter and receive interview transcripts, stock profiles and investment ideas: http://eepurl.com/cHxJ39 Luminex Resources is an MSE sponsor. The forward-looking statement found in Luminex’s most-recent presentation applies to the content of this interview. The content found on MiningStockEducation.com is for informational purposes only and is not to be considered personal legal or investment advice or a recommendation to buy or sell securities or any other product. It is based on opinions, SEC filings, current events, press releases and interviews but is not infallible. It may contain errors and MiningStockEducation.com offers no inferred or explicit warranty as to the accuracy of the information presented. If personal advice is needed, consult a qualified legal, tax or investment professional. Do not base any investment decision on the information contained on MiningStockEducation.com or our videos. We may hold equity positions in and/or be compensated by some of the companies featured on this site and therefore are biased and hold an obvious conflict of interest. MiningStockEducation.com may provide website addresses or links to websites and we disclaim any responsibility for the content of any such other websites. The information you find on MiningStockEducation.com is to be used at your own risk. By reading MiningStockEducation.com, you agree to hold MiningStockEducation.com, its owner, associates, sponsors, affiliates, and partners harmless and to completely release them from any and all liabilities due to any and all losses, damages, or injuries (financial or otherwise) that may be incurred.

The Lumina Group has been delivering results since 2004. During that time it has returned nearly 10 to 1 to investors. Luminex Resources came out of Luminex Gold. Its  Ecuador projects with their highly promising geological prospects show great potential. They've got two high powered joint ventures underway, with heavyweight partners Anglo American and BHP who are moving aggressively to bring the Tarqi and Pegasus projects to fruition. CEO Marshall Koval's 40 years of mining experience is well positioned to move the Company forward. Scott Hicks is excited to be part of the team and his diverse finance background has put him in the right place at the right time. 

The Lumina Group has been delivering results since 2004. During that time it has returned nearly 10 to 1 to investors. Luminex Resources came out of Luminex Gold. Its  Ecuador projects with their highly promising geological prospects show great potential. They've got two high powered joint ventures underway, with heavyweight partners Anglo American and BHP who are moving aggressively to bring the Tarqi and Pegasus projects to fruition. CEO Marshall Koval's 40 years of mining experience is well positioned to move the Company forward. Scott Hicks is excited to be part of the team and his diverse finance background has put him in the right place at the right time. 

Buyers and sellers want choices regarding what to buy and sell and where to buy and sell it.  Trading stocks for investors is no different, as choice matters there too.  We talk with Jon Clark, the CEO of Luminex, about his efforts building a company with the mission of affording institutional investors another choice centered on trading a large block of shares, rather than accessing the moment-to-moment liquidity of stock markets.  Luminex, which actually is owned by institutional investors, is a stock trading venue for blocks of at least 5000 shares traded by institutional investors.  Luminex’s business is one part of equity market structure, which needs to keep up as technology and market conditions change. 

This week, Jonathan Clark, CEO of Luminex, and David Hagen, Luminex’s head of product, join the podcast to look at some of the challenges and opportunities that traders on the buy side face in today’s evolving, increasingly-automated market (3:30). Also, at the start, Anthony gives an update on the Waters Asia event taking place this week.

Interview with Marshall Koval, CEO of Luminex Resources (TSX-V: LR), a Gold Explorer and Developer in Ecuador. Part of Ross Beaty's Lumina Group. A very experienced management team with a track record of delivering returns to shareholders on Copper and Gold projects in South America.They have earn in deals with BHP, Anglo American and First Quantum in place.We discuss these topics and more:Lumina Group Structure and Track Record: Raising $175M & Giving Back $1.5B to Shareholders Mining in Equador Shareholders and Breakdown of the Corporate Structure JV's with BHP, Anglo American and First QuantumCompany page: https://luminexresources.com/Make smarter investment decisions, subscribe here: https://www.cruxinvestor.comFor FREE unbiased investment information, follow us on Twitter and LinkedIn:https://twitter.com/cruxinvestorhttps://www.linkedin.com/company/crux-investor/Take advantage, hear it here first: https://www.youtube.com/CRUXinvestor

The price of gold rose as high as $1350 (August futures basis) in overnight trading on Wednesday before it was pounded back down to $1345 in the London and New York paper gold markets ahead of the highly anticipated Fed interest rate policy decision. The Mining Stock Journal to update subscribers on Integra Resources analysis. Torex Gold announced a maiden underground mineral reserve estiamte and resource estimate for the El Limon deep zone at its El Limon Guajes mining complex in southwest Mexico. Gowest and Luminex announce new finance packages. Crystal Lake Mining has expanded the size of its Newmont Lake project by approximately 25%. We'd like to thank our sponsors! Integra Resources trades on the TSX-V under ITR and the OTCQX under IRRZF. Integra Resource is advancing its past producing DeLamar (DeL - a - Marr ) Gold-Silver project in SW Idaho through aggressive drilling and exploration. An updated Resources Estimate is expected in Q2 and a maiden PEA in H2 2019. The management of Integra successfully sold its previous brownfields project for C$590 million in summer 2017. Read more about the company and its successful management team at integraresources.com. Pacific Empire Minerals Corp. is a junior exploration company focused on the discovery of gold-rich copper deposits in British Columbia, Canada. Pacific Empire trades on the TSX Venture Exchange under the symbol PEMC and on the OTCQB markets under the symbol PEMSF. The Company currently has a very tight share structure. Pacific Empires’ unique approach to the prospect generator business model incorporates the Company’s own reverse circulation drill to advance projects beyond that of typical prospect generators. The focus for Pacific Empire during 2019 is its Babine Porphyry Belt projects in central British Columbia where Pacific Empire has assembled a 17,000 hectare land position over the past 12 months. During 2019, Pacific Empire is also planning aggressive reverse circulation drill programs on its Sat, Bulkley and Paragon properties. More information on Pacific Empire can be found at pemcorp.ca. Brixton Metals is a precious metals exploration and development company which owns four high-potential gold silver and base metals project in both the US and in Canada. It’s Atlin Gold Project in British Columbia has shown exceptional exploration potential, returning up to 509 grams per ton gold over 5.57 meters at the project’s Yellowjacket zone. Read more about Atlin and the other projects under Brixton’s portfolio by visiting brixtonmetals.com. Brixton trades on the TSX venture under BBB and on the US OTC with BBBXF. Western Copper and Gold is focused on developing the world-class Casino project in Canada's Yukon Territory. The Casino project consists of an impressive 10 billion pounds of copper and 18 million ounces of gold in an overall resource. Western Copper and Gold trades on the TSX and the NYSE American with WRN. Be sure to follow the company via their website, www.westerncopperandgold.com. Mining Stock Daily is produced by: www.clearcreekdigital.com www.investmentresearchdynamics.com (Mining Stock Journal)

Ready or not, we're diving into marriage talks. First up: Johnna and Will. Despite Johnna breaking up with Will multiple times and Will sending Johnna to the ER with a panic attack over budget talks, the Holds are still doing something right. Listen up, and take notes on keeping marriage fun with the Holds. Johnna's got the goods on some fantastic (and affordable!) leggings by 90 degrees that are available from Amazon. She's also loving the Luminex teeth whitening strips. Laura's more frequent work outs have her running for her Sparkly Soul headbands (Get 20% off with SUMMER19 and free shipping for orders over $25). And if you're looking for a new lip color with staying power to take you into summer, Laura's giving Limelife by Alcone's Enduring Lip Color two thumbs up! Her favorite shades are Wedding Cake and Macaroon. Thanks for joining us this week! Be sure to listen next week for part two with The Rev and Laura! --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app

Silver tested its 200 day moving average but closed comfortably above it while gold continues its attempt to break above its 200 day moving average. Westhaven Ventures, Corvus Gold, and Osisko Mining all shared impressive exploration results from their respected properties. Equinox Gold updates its resource estimates from both Brazil and California. Luminex finds a third major partner for its portfolio of projects while Wolfden receives assistance from Kinross. Boreal Metals is set to begin drilling at Gumsberg in Sweden. Thank you to our sponsors! Integra Resources trades on the TSX-V under ITR and the OTCQX under IRRZF. Integra Resource is advancing its past producing DeLamar (DeL - a - Marr ) Gold-Silver project in SW Idaho through aggressive drilling and exploration. An updated Resources Estimate is expected in Q2 and a maiden PEA in H2 2019. The management of Integra successfully sold its previous brownfields project for C$590 million in summer 2017. Read more about the company and its successful management team at integraresources.com. Minera Alamos is traded with the symbol MAI on the TSX-Venture Exchange and with MAIFF in the US OTC Markets. Minera is an advanced stage exploration and development company with multiple low cap-ex projects in Mexico. Read more about their development strategies at mineraalamos.com. Brixton Metals is a precious metals exploration and development company which owns four high-potential gold silver and base metals project in both the US and in Canada. It’s Atlin Gold Project in British Columbia has shown exceptional exploration potential, returning up to 509 grams per ton gold over 5.57 meters at the project’s Yellowjacket zone. Read more about Atlin and the other projects under Brixton’s portfolio by visiting brixtonmetals.com. Brixton trades on the TSX venture under BBB and on the US OTC with BBBXF. Western Copper and Gold is focused on developing the world-class Casino project in Canada's Yukon Territory. The Casino project consists of an impressive 10 billion pounds of copper and 18 million ounces of gold in an overall resource. Western Copper and Gold trades on the TSX and the NYSE American with WRN. Be sure to follow the company via their website, www.westerncopperandgold.com. Mining Stock Daily is produced by: www.clearcreekdigital.com www.investmentresearchdynamics.com (Mining Stock Journal)

When we think of missions, we often think of crossing oceans to witness to unreached people groups. But in reality, there are unreached people right here in our American cities. On this week’s podcast we have Nate Bull and Mark Van Andel from Hesed Community Church in Detroit. They tell of their ministry in some […]

Last week on the podcast Randy Weener talked about small churches and how some of them are at the end of their life cycle. This week Doug interviews Jason Vermeulen about his experience pastoring Casnovia Reformed Church during its final days and the time leading up to the end. [00:00:20] Introduction to Casnovia Reformed Church […]

The bigger the better, right? Well, not necessarily. Small churches have advantages that a big church couldn’t have. This week Doug interviews Randy Weener, Classis Leader for the Great Lake City Classis in Michigan. They discuss small churches – their advantages, disadvantages, and unique opportunities. [00:00:30] Defining a small church A small church can be […]

How do we love and befriend our Muslim neighbors so that we can introduce them to our best friend, Jesus? On this week’s podcast, Doug interviews Agshin Jafarov. Agshin works with RCA Global Missions to help resettle many refugees in the Great Lakes Region. During this interview, they discuss Agshin’s experiences working with Muslim refugees […]

Show Notes On this week’s podcast episode, Doug is interviewing Curry Pikkaart, Classis Leader for the Southwest Michigan Classis. The topic of their conversation is based on Curry’s blog post, To Catch the Wind, Hoist Your Sails, about how to persevere through trying and empty  times while waiting for the Holy Spirit’s wind in our […]

On this week’s podcast, John Messer, explains the ins and outs of Robert Kelly’s Follower Matrix and how that relates to discipleship and leadership development in your churches.

On today’s episode, we have Art Wiers, Church Health Catalyst for Luminex, talk about the lifecycle of a church from birth to decline. The reality is that all churches fall somewhere on this cycle and it’s important for leaders to know which stage theirs falls into. Learn how church life cycles leads to effectively starting […]

Biotherapeutic drugs such as monoclonal antibodies (mAbs) have the potential to induce immunogenicity; therefore, it is critical to perform an immunogenicity assessment to ensure drug efficacy and patient safety. In general, an immunogenicity assessment is performed in a multi-tiered approach: screening of anti-drug antibodies (ADA), confirmatory test, titer assessment, characterization of ADA for neutralizing drug activity and isotyping. The goal of our work is to develop multiplex approaches on various platforms including Meso Scale Discovery (MSD), Luminex and Delfia for ADA characterization. To learn more, please visit http://www.PEGSummit.com/Immunogenicity/

Out of the blue we've heard from some smart people interested in this obscure molecular diagnostics company.  Yet it seems few really know what's going on in this space.  All the focus is on the FDA clearance of Luminex's new platform, Aries, which was designed to appeal to hospitals that might otherwise send out complex molecular tests to academic centers or big labs.  In this podcast, Bill Baker, CFA, reveals how despite murky corporate-level profit patterns and excitement about Aries, a quietly building strength in high-margin royalties, assays, and consumables separates Luminex from the rest of the pack.  He shares his insight from years of following a number of molecular diagnostic firms, and debunks misconceptions of where profitability really originates at competitors that would be affected by the launch of Aries.  Next week, Bill travels to attend the Association for Molecular Pathology annual meeting in Austin, TX. 

Background: There has been a long held belief that patients with drug-susceptible TB are non-infectious after two weeks of therapy. Recent microbiological and epidemiological evidence has challenged this dogma, however, the nature of the Mtb-specific cellular immune response during this period has not been adequately investigated. This knowledge could be exploited in the development of immunological biomarkers of early treatment response. Methods: Cellular response to four Mtb infection phase-dependent antigens, ESAT-6/CFP-10 fusion protein and three DosR encoded proteins (Rv1733c, Rv2029c, Rv2628) were evaluated in a Ghanaian TB cohort (n=20) before and after 2 weeks of anti TB therapy. After 6-days in vitro stimulation, Peripheral blood mononuclear cell (PBMC) culture supernatant was harvested and the concentration of IFN-gamma, Granzyme B, IL-10, IL-17, sIL2R alpha and TNF-alpha were determined in a 6-plex Luminex assay. Frequencies of IFN-gamma + CD4 and CD8 T cells were also determined in an intracellular cytokine assay. Results: All antigens induced higher levels of IFN-gamma, followed by Granzyme B, TNF-alpha and IL-17 and low levels of IL-10 and sIL-2R-alpha in PBMC before treatment and after 2 weeks of treatment. Median cytokine levels of IFN-gamma, Granzyme B, IL-17 and sIL-2R-alpha increased during week two, but it was significant for only Rv1733-specific production of Granzyme B (P = 0.013). The median frequency of antigen specific IFN-gamma + CD4 T cells increased at week two; however, only the increase in the ESAT-6/CFP-10-specific response was significant (P = 0.0008). In contrast, the median frequency of ESAT-6/CFP-10-specific IFN-gamma + CD8 T cell responses declined during week two (P = 0.0024). Additionally, wide inter-individual variation with three distinct patterns were observed; increase in all cytokine levels, decrease in all cytokine levels and fluctuating cytokine levels after 2 weeks of treatment. Conclusion: The second week of effective chemotherapy was characterized by a general increase in cytokine response to Mtb-specific antigens suggestive of an improvement in cellular response with therapy. However, the wide inter-individual variation observed would limit the utility of cytokine biomarkers during this period.

Today in FirstWord:

Blutgerinnung und Entzündung sind zwei stark miteinander verknüpfte Vorgänge im menschlichen Körper. Es ist gängige Meinung, dass während einer Sepsis die systemische Entzündung unweigerlich zu einer Aktivierung des Gerinnungssystems und einer gleichzeitigen Inhibition des blutgerinnungshemmenden Systems sowie der Fibrinolyse führt. Durch die massive Aktivierung der Gerinnung kommt es zu einer sogenannten Verbrauchskoagulopathie, bei der vor allem die antikoagulatorische Kapazität stark reduziert ist. So ist die Aktivität von ATIII und APC, zwei der wichtigsten körpereigenen Gerinnungsinhibitoren, während der Sepsis erheblich vermindert. Rekombinant hergestelltes APC hat als Xigris® seit 2002 die europäische Zulassung zur Behandlung der schweren Sepsis. In einer klinischen Studie der Phase 3 wurde eine Reduktion der 28-Tage Sterblichkeit durch die Gabe von APC bei Patienten mit schwerer Sepsis festgestellt. Im Gegensatz zu APC zeigte ATIII in einer Studie der Phase 3 an Patienten mit schwerer Sepsis keine Reduktion der 28-Tage Sterblichkeit. Es ist generell akzeptiert, dass das septische Mehrorganversagen durch die systemische Immunantwort des Organismus auf eine Infektion und die daraus resultierende überschießende systemische Freisetzung inflammatorischer Mediatoren vermittelt wird. Die Freisetzung dieser Mediatoren erfolgt unter anderem aus Monozyten. Durch den entzündlichen Stimulus während einer Verletzung oder Sepsis wird auf Monozyten neben der Freisetzung von Zytokinen auch TF induziert, der Rezeptor und Aktivator von FVII. Der Komplex aus TF und FVIIa stellt den Anfangspunkt der exogenen Gerinnung dar. Seit einigen Jahren wird rFVIIa als „rescue therapy“ zur Kontrolle schwerer traumatisch verursachter Hämorrhagien diskutiert. Dabei soll durch die Gabe von rFVIIa die Gerinnung spezifisch am Ort der Verletzung verstärkt werden. Da durch das Trauma und die damit verbundene Entzündungsreaktion Monozyten vermutlich TF exprimieren, stellen auch diese Zellen einen potentiellen Angriffspunkt für rFVIIa dar. Das Ziel der vorgelegten Arbeit war, mögliche gerinnungsunabhängige immunmodulatorische Eigenschaften dieser, in der Intensivmedizin verwendeten, körpereigenen Substanzen zu untersuchen. Im Speziellen sollte die Auswirkung der Pro- bzw. Antikoagulantien auf die LPS-induzierte Zytokinfreisetzung von Monozyten untersucht werden, ein wichtiger Bestandteil in der Entstehung von Sepsis und MODS. Dazu wurde ein Versuchsmodell mit einer humanen, monozytären Zelllinie, MonoMac6, etabliert. Die Produktion von IL-1β, IL-8 und TNFα wurde intrazellulär mit Hilfe der Durchflusszytometrie bestimmt. Im Zellkulturüberstand wurden die Konzentrationen von IL-1β, IL-8, IL-10 und TNFα mit einem Luminex-100 System gemessen. Zusätzlich wurde für rFVIIa der Einfluss auf die LPS-induzierte IL-1β-, IL-6-, IL-8- und TNFα-Synthese von CD14+ Monozyten in PBMCs durchflusszytometrisch erfasst. In der vorgelegten Arbeit konnte eine limitierende Wirkung von APC und ATIII auf die LPS-induzierte Zytokinproduktion von Monozyten festgestellt werden. APC verminderte die IL-1β-, IL-10- und TNFα-Ausschüttung signifikant, wobei Überstandsmessungen die eindeutigsten Ergebnisse zeigten. Der Effekt von ATIII ließ sich durchflusszytometrisch besser bestimmen, als aus dem Überstand. Es zeigte sich eine signifikant verminderte LPS-induzierte IL-1β- und TNFα-Produktion der Monozyten. Zusätzlich wurde der Effekt von Heparin auf die ATIII-Wirkung untersucht, da es mehrere Hinweise auf eine negative Beeinflussung der ATIII-Therapie in der Sepsis durch gleichzeitige Gabe von Heparin gibt. In der vorgelegten Arbeit konnte interessanter Weise kein antagonisierender Effekt von Heparin auf die immunologische Wirkung von ATIII festgestellt werden. Neben dem positiven Effekt durch die Wiederherstellung der Antikoagulation während der Sepsis, kann APC auch zur Wiederherstellung des Gleichgewichts zwischen Pro- und Antiinflammation beitragen. APC vermindert sowohl die Synthese pro-, als auch die antiinflammatorisch wirkender Mediatoren, was eine Erklärung für die Wirksamkeit bei dem sehr heterogenen Kollektiv der Sepsispatienten sein könnte. ATIII reduziert nach unseren Ergebnissen lediglich die Synthese der proinflammatorischen Zytokine TNFα und IL-1β, nicht aber die von IL-10. Geht man davon aus, dass APC deshalb wirksam ist, weil es sowohl eine überschießende Pro- als auch Antiinflammation dämpfen kann, wäre das eine Erklärung für das Fehlen des klinischen Wirksamkeitsnachweises für ATIII bei Patienten mit schwerer Sepsis. Für rFVIIa ergab sich ein messbarer, aber nicht eindeutig charakterisierbarer immunmodulatorischer Effekt auf die LPS-induzierte Zytokinproduktion von Monozyten. Bei MonoMac6 Zellen zeigte sich ein leicht begrenzender Effekt auf die IL-8- und TNFα-Produktion. Die Behandlung von PBMCs mit rFVIIa ergab keine veränderte LPS-induzierte Zytokinfreisetzung von CD14+ Monozyten. In verschiedenen Versuchsabläufen wurden MonoMac6 Zellen zur Erhöhung der TF-Expression vor der Inkubation mit rFVIIa mit TNFα oder LPS behandelt. Dabei zeigte sich je nach Messmethode und Vorbehandlung außer einer geringen Steigerung der TNFα-Synthese LPS-vorbehandelter Monozyten kein Effekt. Zusätzlich wurde eine Transfektion der MonoMac6 Zellen mit TF durchgeführt. In Versuchen mit dieser Zelllinie ergab sich eine erhöhte TNFα-Synthese unter rFVIIa-Einfluss. Dieses Ergebnis ist jedoch mit Vorsicht zu betrachten, da die Reaktion der transfizierten Zellen auf LPS alleine im Kontrollexperiment nicht der des Wildtyps entsprach. Eine rFVIIa-induzierte Bildung von Thrombin kann ebenfalls in die Immunreaktion eingreifen, dies illustriert die in der vorgelegten Arbeit unter Thrombineinfluss gemessene, stark verminderte LPS-induzierte IL-10 Ausschüttung. Allerdings konnte der direkte immunmodulatorische Effekt von rFVIIa weder mit der Komplexbildung aus TF und rFVIIa noch mit der von rFVIIa vermittelten Produktion von Thrombin in Verbindung gebracht werden. Die immunmodulatorische Wirkung von rFVIIa auf die LPS-induzierte Zytokinproduktion von Monozyten konnte mit den in der vorgelegten Arbeit verwendeten Modellen nicht abschließend geklärt werden und lässt noch viel Raum für weitere Untersuchungen. Transfektionsversuche mit anderen monozytären Zelllinien oder die Selektion von TF-exprimierenden Immunzellen aus kritisch kranken Patienten wären mögliche Versuchsansätze für die Zukunft. Auch ein geeigneter Stimulus zur Induktion von TF auf isolierten humanen Monozyten, der nicht gleichzeitig die Zytokinsynthese anregt, würde vielversprechende Möglichkeiten bieten.

Ambient air pollution can alter cytokine concentrations as shown in vitro and following short-term exposure to high air pollution levels in vivo. Exposure to pollution during late pregnancy has been shown to affect fetal lymphocytic immunophenotypes. However, effects of prenatal exposure to moderate levels of air pollutants on cytokine regulation in cord blood of healthy infants are unknown. In a birth cohort of 265 healthy term-born neonates, we assessed maternal exposure to particles with an aerodynamic diameter of 10 µm or less (PM₁₀), as well as to indoor air pollution during the last trimester, specifically the last 21, 14, 7, 3 and 1 days of pregnancy. As a proxy for traffic-related air pollution, we determined the distance of mothers' homes to major roads. We measured cytokine and chemokine levels (MCP-1, IL-6, IL-10, IL-1ß, TNF-α and GM-CSF) in cord blood serum using LUMINEX technology. Their association with pollution levels was assessed using regression analysis, adjusted for possible confounders. Mean (95%-CI) PM₁₀ exposure for the last 7 days of pregnancy was 18.3 (10.3-38.4 µg/m³). PM₁₀ exposure during the last 3 days of pregnancy was significantly associated with reduced IL-10 and during the last 3 months of pregnancy with increased IL-1ß levels in cord blood after adjustment for relevant confounders. Maternal smoking was associated with reduced IL-6 levels. For the other cytokines no association was found. Our results suggest that even naturally occurring prenatal exposure to moderate amounts of indoor and outdoor air pollution may lead to changes in cord blood cytokine levels in a population based cohort.